EBS
vs
S&P 500
EBS
S&P 500
Over the past 12 months, EBS has significantly outperformed S&P 500, delivering a return of +52% compared to the S&P 500's +14% growth.
Stocks Performance
EBS vs S&P 500
Performance Gap
EBS vs S&P 500
Performance By Year
EBS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Emergent BioSolutions Inc
Glance View
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.